FDA Places Hold on BioMarin’s PKU Gene TherapyClinical Hold, Clinical Trials, FDA, Gene Therapy, Phenylketonuria (PKU), R&DThe U.S. Food and Drug Administration placed a clinical hold on BioMarin Pharmaceutical’s BMN 307 Phearless Phase I/II study. Read more September 7, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/09/FDA-Slaps-a-Hold-on-BioMarins-PKU-Gene-Therapy-BioSpace-9-7-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-09-07 11:38:562021-09-07 13:33:55FDA Places Hold on BioMarin’s PKU Gene Therapy